Nanotech Investing Nuvation Bio Enrolls First Patient in TRUST-IV Phase 3 Study of IBTROZI for the Adjuvant Treatment of ROS1-Positive Early-Stage Non-Small Cell Lung Cancer
Nanotech Investing Nuvation Bio Receives Approval from Japan's Ministry of Health, Labour and Welfare for IBTROZITM for Patients with Advanced ROS1-positive Non-Small Cell Lung Cancer
Nanotech Investing Nuvation Bio Announces New Data from Pivotal Clinical Studies of IBTROZI in Advanced ROS1-Positive Non-Small Cell Lung Cancer at 2025 World Conference on Lung Cancer
Standard Uranium Announces Expansion of Davidson River Drill Program and Provides Update on Private Placement and LIFE Offering
